Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA; Division of General Pediatrics, Department of Pediatrics, Boston University School of Medicine and Boston Medical Center, Boston, MA; Grayken Center for Addiction, Boston Medical Center, Boston, MA. Electronic address: https://twitter.com/
Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA; Grayken Center for Addiction, Boston Medical Center, Boston, MA.
Ann Emerg Med. 2020 Jan;75(1):29-38. doi: 10.1016/j.annemergmed.2019.07.030. Epub 2019 Oct 4.
Nonfatal opioid overdose represents an opportunity to engage young adults into using medication for opioid use disorder. We seek to describe characteristics of young adults who experience nonfatal overdose and estimate rates of and time to medication for opioid use disorder for young adults relative to those aged 26 to 45 years.
We conducted a cohort study using retrospective administrative data of 15,281 individuals aged 18 to 45 years who survived an opioid-related overdose in Massachusetts between 2012 and 2014, using deidentified, individual-level, linked data sets from Massachusetts government agencies. We described patient characteristics stratified by age (18 to 21, 22 to 25, and 26 to 45 years) and evaluated multivariable Cox proportional hazards models to compare rates of medication for opioid use disorder receipt, controlling for age, sex, history of mental health disorders, and addiction treatment.
Among 4,268 young adults in the year after nonfatal overdose, 28% (n=336/1,209) of those aged 18 to 21, 36% (n=1,097/3,059) of those aged 22 to 25 years, and 36% (n=3,916/11,013) of those aged 26 to 45 years received medication for opioid use disorder. For individuals aged 18 to 21 and 22 to 25 years, median time to buprenorphine treatment was 4 months (interquartile range 1.7 to 1.8 months); to methadone treatment, 4 months (interquartile range 2.8 to 2.9 months); and to naltrexone treatment, 1 month (interquartile range 1 to 1 month). Individuals aged 18 to 21 years were less likely (adjusted hazard ratio 0.60 [95% confidence interval 0.45 to 0.70]) to receive methadone than those aged 22 to 25 and 26 to 45 years. Individuals aged 18 to 21 years and those aged 22 to 25 years were more likely to receive naltrexone (adjusted hazard ratio 1.65 [95% confidence interval 1.36 to 2.00] and 1.41 [95% confidence interval 1.23 to 1.61], respectively) than those aged 26 to 45 years.
One in 3 young adults received medication for opioid use disorder in the 12 months after surviving an overdose. Type of medication for opioid use disorder received appeared to be age associated. Future research should focus on how medication choice is made and how to optimize the emergency department for medication for opioid use disorder initiation after nonfatal overdose.
非致命性阿片类药物过量代表了一个机会,可以让年轻人开始使用治疗阿片类药物使用障碍的药物。我们旨在描述经历非致命性过量的年轻人的特征,并估计年轻人相对于 26 至 45 岁年龄组使用治疗阿片类药物使用障碍药物的比率和时间。
我们使用马萨诸塞州政府机构的匿名、个体层面、链接数据集,进行了一项回顾性队列研究,共纳入了 15281 名在 2012 年至 2014 年间经历过阿片类药物相关过量的 18 至 45 岁个体。我们按年龄(18 至 21 岁、22 至 25 岁和 26 至 45 岁)对患者特征进行分层,并评估多变量 Cox 比例风险模型,以比较接受治疗阿片类药物使用障碍药物的比率,同时控制年龄、性别、精神健康障碍史和成瘾治疗。
在非致命性过量后的一年中,4268 名年轻成年人中有 28%(n=336/1209)年龄在 18 至 21 岁,36%(n=1097/3059)年龄在 22 至 25 岁,36%(n=336/11013)年龄在 26 至 45 岁的人接受了治疗阿片类药物使用障碍药物。对于年龄在 18 至 21 岁和 22 至 25 岁的个体,接受丁丙诺啡治疗的中位数时间为 4 个月(四分位距 1.7 至 1.8 个月);接受美沙酮治疗的中位数时间为 4 个月(四分位距 2.8 至 2.9 个月);接受纳曲酮治疗的中位数时间为 1 个月(四分位距 1 至 1 个月)。与 22 至 25 岁和 26 至 45 岁的人相比,年龄在 18 至 21 岁的人接受美沙酮治疗的可能性更低(调整后的危险比 0.60[95%置信区间 0.45 至 0.70])。与 26 至 45 岁的人相比,年龄在 18 至 21 岁的人和年龄在 22 至 25 岁的人更有可能接受纳曲酮治疗(调整后的危险比 1.65[95%置信区间 1.36 至 2.00]和 1.41[95%置信区间 1.23 至 1.61])。
三分之一的年轻成年人在经历过量后 12 个月内接受了治疗阿片类药物使用障碍的药物。接受的治疗阿片类药物使用障碍药物的类型似乎与年龄有关。未来的研究应侧重于如何做出药物选择以及如何优化急诊科,以在非致命性过量后开始使用治疗阿片类药物使用障碍的药物。